Oncology News | pharmaphorum

News

Now Iktos teams up with Pierre Fabre in oncology

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

News

$100 bill with missing puzzle pieces to be inserted

Parabilis scores $305m in bumper biofinancing week

Money has flooded into biotechs this week, with Parabilis raising $305m and five other start-ups closing nine-figure private rounds.

News

Spinning top in black and white, revolving

Report says MSD is in talks to buy Revolution Meds

MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

News

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.

News

Amgen inks $840m takeover of UK's Dark Blue Therapeutics

Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

News

Aktis Oncology files much-expanded IPO

Aktis Oncology has filed its IPO, seeking to raise up to around $210 million in what could be the first biotech listing on the Nasdaq in 2026.

Now Iktos teams up with Pierre Fabre in oncology

Parabilis scores $305m in bumper biofinancing week

Report says MSD is in talks to buy Revolution Meds

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Amgen inks $840m takeover of UK's Dark Blue Therapeutics

Aktis Oncology files much-expanded IPO

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks